Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| GIP/GLP-1/FGF21 Fusion Protein treating NASH, T2DM, Hyperlipoidemia | NASH, T2DM, Hyperlipoidemia | Preclinical |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| FG1-H82Q3 | Human | Biotinylated Human FGF-21 Protein, His,Avitag™ |  |
|
|
| FG1-H5243 | Human | Human FGF-21 Protein, His Tag |  |
|
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Pegozafermin | BIO89-100; TEV-47948 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| Efruxifermin | AKR-001; AMG-876; EFX; Fc-FGF21(RGE) | Phase 3 Clinical | Amgen Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis; Diabetes Mellitus | Details |
| Efimosfermin alfa | LLF-580; BOS-580 | Phase 2 Clinical | Novartis Pharma Ag | Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity | Details |
| Recombinant human FGF21 Fc fusion protein(Anyuan Pharmaceutical) | AP-025; TQA2225; TQA-2225 | Phase 2 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| HEC-88473 | HEC-88473; HEC88473; APL-18881 | Phase 2 Clinical | Dongguan Hec Taigen Biopharmaceuticals Co Ltd | Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Hepatitis; Obesity | Details |
| YH-25724 | YH25724; YH-25724 | Phase 1 Clinical | Yuhan Corp | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| MWN-105 | MWN-105 | Phase 1 Clinical | Shanghai Minwei Biotechnology Co Ltd | Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight; Hyperlipidemias | Details |
| AP-026 | TQA2226; AP026; AP-026; TQA-2226 | Phase 1 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Hyperlipidemias; Overweight | Details |
This web search service is supported by Google Inc.
A-Z
